NewLink Genetics Appoints Chad A. Johnson to Board of Directors
March 21 2018 - 9:00AM
NewLink Genetics Corporation (NASDAQ:NLNK) today announced the
appointment of Chad A. Johnson, 39, to the Company's Board of
Directors. In connection with this appointment, the Company's
Board expanded from seven directors to eight.
"We welcome Mr. Johnson to our Board of
Directors," said Charles J. Link, Jr, MD, Chairman and Chief
Executive Officer. “His experience as a corporate officer,
including governance, legal, and strategic business issues are
important additions to NewLink Genetics.”
Mr. Johnson is currently Vice President, General
Counsel for the Stine Seed Company, the world’s largest private
seed company. In that role, Chad is responsible for managing
all legal issues of concern to the company.
Prior to his position with Stine Seed Company,
Chad was the Assistant Corporate Secretary and Senior Corporate
Counsel for Renewable Energy Group, Inc., the largest supplier of
advanced biofuels by volume in North America. In addition to
his role as a corporate officer, Chad was a senior in-house
attorney for the company where he helped advance the company’s
strategic expansion into Europe and other merger and acquisition
activities, managed the company’s intellectual property portfolio
and managed the legal aspects of the company’s securities and
public filings. Before joining Renewable Energy Group, Chad
spent eight years in roles of increasing responsibility at DuPont
Pioneer, a subsidiary of DuPont and a global leading seed and
agriculture biotechnology company. In those roles, he
provided legal guidance to a variety of businesses in connection
with mergers and acquisitions, strategic collaborations with
industry partners and compliance initiatives. Chad is
admitted to practice law in the state of Iowa and before the United
States Patent and Trademark Office.
Mr. Johnson graduated from Iowa State University
with a Master of Science in Crop Production and Physiology and
received his J.D. from Drake University Law School.
“It’s an exciting time to be joining NewLink
Genetics," said Mr. Johnson. “I look forward to working with the
Board and the management team as the company advances toward
multiple data disclosures from its clinical programs in cancer
indications.”
About NewLink Genetics
Corporation
NewLink Genetics is a late-stage
biopharmaceutical company focusing on discovering, developing and
commercializing novel immuno-oncology product candidates to improve
the lives of patients with cancer. NewLink Genetics' IDO pathway
inhibitors are designed to harness multiple components of the
immune system to combat cancer. For more information, please
visit www.newlinkgenetics.com and follow us on Twitter
@NLNKGenetics.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements of NewLink that involve substantial
risks and uncertainties. All statements contained in this press
release are forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. The words
"guidance," "upcoming," "will," "plan," "anticipate,"
"approximate," "expect," or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include,
among others, statements about NewLink Genetics' financial guidance
for 2018; results of its clinical trials for product candidates;
its timing of release of data from ongoing clinical studies; its
plans related to moving additional indications into clinical
development; NewLink Genetics' future financial performance,
results of operations, cash position and sufficiency of capital
resources to fund its operating requirements; and any other
statements other than statements of historical fact. Actual results
or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that
NewLink makes due to a number of important factors, including those
risks discussed in "Risk Factors" and elsewhere in NewLink
Genetics' Annual Report on Form 10-K for the year ended December
31, 2017 and other reports filed with the U.S. Securities and
Exchange Commission (SEC). The forward-looking statements in this
press release represent NewLink's views as of the date of this
press release. NewLink anticipates that subsequent events and
developments will cause its views to change. However, while it may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to do so. You
should, therefore, not rely on these forward-looking statements as
representing NewLink Genetics' views as of any date subsequent to
the date of this press release.
Investor Contact:
Lisa MillerDirector of Investor RelationsNewLink
Genetics515-598-2555lmiller@linkp.com
Media Contact:
Sharon CorreiaVP, Integrated
CommunicationsLaVoieHealthScience617-374-8800, ext.
105scorreia@lavoiehealthscience.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/5937c758-39ab-41f3-96a3-f7ce581958c9
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024